These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
408 related articles for article (PubMed ID: 10189847)
1. Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma. van Sandick JW; van Lanschot JJ; Kuiken BW; Tytgat GN; Offerhaus GJ; Obertop H Gut; 1998 Aug; 43(2):216-22. PubMed ID: 10189847 [TBL] [Abstract][Full Text] [Related]
2. [Impact of endoscopic surveillance of Barrett's esophagus on survival of patients with esophageal adenocarcinoma]. Incarbone R; Bonavina L; Bassi F; Peracchia A Chir Ital; 2002; 54(5):591-6. PubMed ID: 12469454 [TBL] [Abstract][Full Text] [Related]
3. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance? Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485 [TBL] [Abstract][Full Text] [Related]
4. Outcome of esophageal adenocarcinoma detected during endoscopic biopsy surveillance for Barrett's esophagus. Incarbone R; Bonavina L; Saino G; Bona D; Peracchia A Surg Endosc; 2002 Feb; 16(2):263-6. PubMed ID: 11967675 [TBL] [Abstract][Full Text] [Related]
5. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma? Quera R; O'Sullivan K; Quigley EM Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424 [TBL] [Abstract][Full Text] [Related]
6. Diagnosing dysplasia in Barrett's oesophagus still requires Seattle protocol biopsy in the era of modern video endoscopy: results from a tertiary centre Barrett's dysplasia database. Nachiappan A; Ragunath K; Card T; Kaye P Scand J Gastroenterol; 2020 Jan; 55(1):9-13. PubMed ID: 31880176 [No Abstract] [Full Text] [Related]
7. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling. Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207 [TBL] [Abstract][Full Text] [Related]
8. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565 [TBL] [Abstract][Full Text] [Related]
9. A surveillance programme for Barrett's oesophagus in a UK general hospital. Olithselvan A; Gorard DA; McIntyre AS Eur J Gastroenterol Hepatol; 2007 Apr; 19(4):305-9. PubMed ID: 17353694 [TBL] [Abstract][Full Text] [Related]
11. Outcome of adenocarcinoma arising in Barrett's esophagus in endoscopically surveyed and nonsurveyed patients. Peters JH; Clark GW; Ireland AP; Chandrasoma P; Smyrk TC; DeMeester TR J Thorac Cardiovasc Surg; 1994 Nov; 108(5):813-21; discussion 821-2. PubMed ID: 7967662 [TBL] [Abstract][Full Text] [Related]
12. Effect of surveillance of Barrett's oesophagus on the clinical outcome of oesophageal cancer. Fountoulakis A; Zafirellis KD; Dolan K; Dexter SP; Martin IG; Sue-Ling HM Br J Surg; 2004 Aug; 91(8):997-1003. PubMed ID: 15286961 [TBL] [Abstract][Full Text] [Related]
13. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma. Hurschler D; Borovicka J; Neuweiler J; Oehlschlegel C; Sagmeister M; Meyenberger C; Schmid U Swiss Med Wkly; 2003 Sep; 133(37-38):507-14. PubMed ID: 14652799 [TBL] [Abstract][Full Text] [Related]
14. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma. Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177 [TBL] [Abstract][Full Text] [Related]
15. Effect of Barrett's esophagus surveillance on esophageal preservation, tumor stage, and survival with esophageal adenocarcinoma. Grant KS; DeMeester SR; Kreger V; Oh D; Hagen JA; Chandrasoma P; DeMeester TR J Thorac Cardiovasc Surg; 2013 Jul; 146(1):31-7. PubMed ID: 23312980 [TBL] [Abstract][Full Text] [Related]
17. Barrett's oesophagus: optimal strategies for prevention and treatment. Fass R; Sampliner RE Drugs; 2003; 63(6):555-64. PubMed ID: 12656653 [TBL] [Abstract][Full Text] [Related]
18. [Barrett esophagus. Current situation of the risk and surveillance policy]. Robaszkiewicz M Presse Med; 1994 Dec; 23(40):1846-8. PubMed ID: 7899314 [TBL] [Abstract][Full Text] [Related]
19. Daily use of non-steroidal anti-inflammatory drugs is less frequent in patients with Barrett's oesophagus who develop an oesophageal adenocarcinoma. Tsibouris P; Hendrickse MT; Isaacs PE Aliment Pharmacol Ther; 2004 Sep; 20(6):645-55. PubMed ID: 15352913 [TBL] [Abstract][Full Text] [Related]
20. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot. Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]